
Citicol500 mg
Beximco Pharmaceuticals Ltd.
Citicoline Sodium is a naturally occurring nucleotide (cytidine diphosphate-choline, CDP-choline) precursor of phospholipids used mainly as a nootropic/neuroprotective adjunct.
Citicoline Sodium is a naturally occurring nucleotide (cytidine diphosphate-choline, CDP-choline) precursor of phospholipids used mainly as a nootropic/neuroprotective adjunct. It is not an FDA-approved prescription drug in the United States, where it is sold as a dietary supplement, but it is a registered pharmaceutical product in Bangladesh and many other countries. Its uses can be classified by strength of evidence as follows:
Citicoline Sodium is not a cure for stroke, brain injury, or dementia; it is intended to be used in combination with, not instead of, standard medical and rehabilitative care, and the underlying condition should be diagnosed and managed by a physician.
Dosage of Citicoline Sodium should be individualized by the prescribing physician according to indication, severity, and route. Typical dosing ranges used in regional labeling are summarized below; always follow the specific product label and physician's instructions.
| Indication | Adult dose | Notes |
|---|---|---|
| Acute ischemic stroke (adjunct) | 500–2000 mg daily, oral or parenteral, generally started within 24 hours of symptom onset | Used alongside standard acute stroke care, not as a substitute for it |
| Post-stroke cognitive impairment / chronic cerebrovascular disease (adjunct) | 500–1000 mg daily, oral, often in divided doses | Duration guided by physician response assessment; see Duration of Treatment |
| Traumatic brain injury recovery (adjunct) | 500–1000 mg daily, oral or parenteral, as directed by physician | Dose and route depend on injury severity and clinical setting |
| Injectable (IM/IV) use | Typically 500 mg once or twice daily; IV doses given as a slow infusion | For hospital/physician-administered use only; injection site and rate as per product labeling |
Administration: Oral tablets are usually taken with water, with or without food. Injectable Citicoline Sodium must be administered by a qualified healthcare professional via the intramuscular or intravenous route; intravenous administration should be given slowly. Do not exceed the dose or duration recommended by the physician. See Use in Special Populations for pediatric, elderly, hepatic, and renal considerations.
Citicoline Sodium is generally well tolerated. Reported side effects include:
| Frequency | Effects |
|---|---|
| Common | Mild gastrointestinal upset (nausea, diarrhea, stomach discomfort), headache, insomnia or (in some patients) drowsiness |
| Less common | Dizziness, transient changes in blood pressure (hypotension or, rarely, hypertension), skin rash |
| Rare | Parasympathetic (vagotonic) stimulation effects, hypersensitivity reactions |
Patients should seek medical advice if side effects are severe or persistent.
Citicoline Sodium is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.